Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof: wherein A is substituted or unsubstituted monocyclic aryl or monocyclic heterocyclyl; X is a single bond or C(═O); Y is a single bond, CR 5 R 6 NR 7 or C(═O)NR 7 ; R 1 and R 2 are independently hydrogen or substituted or unsubstituted alkyl; R 3 is substituted or unsubstituted aryl or heterocyclyl; R 4 is halogen, substituted or unsubstituted alkyl, alkoxy, aryloxy or heterocyclyloxy, etc.; p is an integer of 0 to 2; q is 0 or 1; m is 0 or 1; n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or bicyclic fused hetero ring.
1. A pharmaceutical composition, comprising a compound of the formula (I), and/or a pharmaceutically acceptable salt or solvate thereof:
wherein:
A is selected from the group consisting of:
X is C(═O);
the group of the formula (II)
represents formula (IV):
wherein:
R 5 , R 6 and R 7 are independently hydrogen or substituted or unsubstituted alkyl;
R 1 and R 2 are independently hydrogen or substituted or unsubstituted alkyl;
R 3 is substituted or unsubstituted phenyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted pyridyl, substituted or unsubstituted pyrimidyl, or substituted or unsubstituted morpholino;
R 4 is each independently selected from the group consisting of:
halogen, cyano, nitro, nitroso, azido, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl;
hydroxy, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted heterocyclyloxy;
mercapto, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted cycloalkylthio, substituted or unsubstituted cycloalkenylthio, substituted or unsubstituted arylthio, substituted or unsubstituted heterocyclylthio;
formyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted cycloalkylcarbonyl, substituted or unsubstituted cycloalkenylcarbonyl, substituted or unsubstituted arylcarbonyl, substituted or unsubstituted heterocyclylcarbonyl;
sulfino, sulfo, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted cycloalkylsulfonyl, substituted or unsubstituted cycloalkenylsulfonyl, substituted or unsubstituted arylsulfonyl, substituted or unsubstituted heterocyclylsulfonyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted cycloalkylsulfinyl, substituted or unsubstituted cycloalkenylsulfinyl, substituted or unsubstituted arylsulfinyl, substituted or unsubstituted heterocyclylsulfinyl, substituted or unsubstituted sulfamoyl; and
substituted or unsubstituted amino;
p is 0
q is 0 or 1;
m is 1;
n is an integer of 0 to 5;
B is benzene, pyrazole, imidazole, pyridine, benzimidazole, indole, pyrrolopyridine, indazole, dihydrobenzoxazole or indoline; and
the pharmaceutical composition has NPY Y5 receptor antagonist activity.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is suitable for preventing or treating obesity or obesity-related diseases, or weight control in obesity.